TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8325063

Group type: EXPERIMENTAL
Intervention: 40 to 60 min after exercise (6 min ergometer cycling) while breathing cold dry (CD) air (temperature = ‐13 degrees C, relative humidity = 0 percent)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 40 to 60 min after exercise while breathing warm humid (WH) air (temperature = 33 degrees C, relative humidity = 100 percent)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cold dry (CD) air
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Warm humid (WH) air
Number of subjects: 8
Study: 3092099

Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride (Trexan) at 300 mg dosage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride (Trexan) at high dosages (greater than recommended for opioid addiction)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride (Trexan) at recommended dosages for opioid addiction
Number of subjects: 0
Study: 29578578

Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg every 4 weeks
Number of subjects: 1991

Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg every 2 weeks
Number of subjects: 1991

Group type: EXPERIMENTAL
Intervention: Sirukumab
Number of subjects: 1991
Study: 27434082

Group type: EXPERIMENTAL
Intervention: 8-s rest interval trial
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 12-s rest interval trial
Number of subjects: 7

Group type: COMPARATOR
Intervention: 20-s rest interval trial
Number of subjects: 7
Study: 24898471

Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 609

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 609
Study: 22704676

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 20721705

Group type: EXPERIMENTAL
Intervention: Comet assay
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no sepsis)
Number of subjects: 48
Study: 18360782

Group type: EXPERIMENTAL
Intervention: INVOS (Somanetics, IL, USA) 5100C cerebral oximeter
Number of subjects: 6
Study: 16115356

Group type: EXPERIMENTAL
Intervention: Olive/soyabean oil long-chain triacylglycerol (LCT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Medium-chain triacylglycerol (MCT)/LCT; 50:50 (w)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both lipid emulsions
Number of subjects: 22
Study: 12072761

Group type: EXPERIMENTAL
Intervention: Cryotherapy (ice applied for the first hour)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No cryotherapy (ice applied for the second hour)
Number of subjects: 12
Study: 10051701

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9000837

Group type: EXPERIMENTAL
Intervention: Capsules (A)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Drops (B)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Tablets (C)
Number of subjects: 18
Study: 2209296

Group type: EXPERIMENTAL
Intervention: Active sensory retraining
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham retraining
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Subsequent strength and coordination training
Number of subjects: 25
Study: 342062

Group type: EXPERIMENTAL
Intervention: Cimetidine (prophylactic use)
Number of subjects: 63

Group type: COMPARATOR
Intervention: No cimetidine (control group)
Number of subjects: 63
Study: 31778862

Group type: EXPERIMENTAL
Intervention: Knowledge, Simulation, and Sharing (KSS) training
Number of subjects: 250
Study: 31437289

Group type: EXPERIMENTAL
Intervention: Our Family Journey (OFJ) intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Written dementia caregiving information (control)
Number of subjects: 60
Study: 28379796

Group type: EXPERIMENTAL
Intervention: RVD plus transplantation
Number of subjects: 700

Group type: COMPARATOR
Intervention: RVD alone
Number of subjects: 700
Study: 26365444

Group type: EXPERIMENTAL
Intervention: co-supplemented hemp seed and evening primrose oils along with advised Hot nature diet
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: co-supplemented oils
Number of subjects: 100

Group type: COMPARATOR
Intervention: olive oil
Number of subjects: 100
Study: 23261129

Group type: EXPERIMENTAL
Intervention: Aripiprazole adjunctive to lithium/valproate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lithium/valproate (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aripiprazole adjunctive to lamotrigine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lamotrigine (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aripiprazole adjunctive to mood stabilizers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mood stabilizer monotherapy
Number of subjects: 0
Study: 21747104

Group type: EXPERIMENTAL
Intervention: E-learning and bimonthly performance feedback
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (joint baseline workshop only)
Number of subjects: 19
Study: 19562929

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Female diabetic patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Male diabetic patients
Number of subjects: 0
Study: 18038496

Group type: EXPERIMENTAL
Intervention: 1310-nm wavelength laser with sapphire contact cooling
Number of subjects: 0
Study: 14746738

Group type: EXPERIMENTAL
Intervention: Written information
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Verbal explanations
Number of subjects: 120

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 120
Study: 11408333

Group type: EXPERIMENTAL
Intervention: Sequential presentation in a temporal forced choice paradigm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simultaneous presentation with a spatial forced choice paradigm
Number of subjects: 0
Study: 9429962

Group type: EXPERIMENTAL
Intervention: Staff training programme
Number of subjects: 5
Study: 8430713

Group type: EXPERIMENTAL
Intervention: Bisoprolol (10 to 20 mg)
Number of subjects: 659

Group type: COMPARATOR
Intervention: Atenolol (50 to 100 mg)
Number of subjects: 659
Study: 3309012

Group type: EXPERIMENTAL
Intervention: Pregestimil
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 19
Study: 29445864

Group type: EXPERIMENTAL
Intervention: Video gaming group (Group A) - 5 hours of playing the laparoscopic video game (Underground) per week for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (Group B) - Avoid gaming beyond normal frequency for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of video gaming group to control group
Number of subjects: 20
Study: 27598398

Group type: EXPERIMENTAL
Intervention: BIS evaluation of sedation with propofol‐remifentanil
Number of subjects: 90

Group type: COMPARATOR
Intervention: Modified observer's assessment of alertness/sedation scale clinical evaluation
Number of subjects: 90
Study: 25006070

Group type: EXPERIMENTAL
Intervention: Ractopamine hydrochloride (RAC; 5 mg/kg)
Number of subjects: 1408

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 1408

Group type: EXPERIMENTAL
Intervention: Immunologically castrated (IC) pigs
Number of subjects: 1408

Group type: COMPARATOR
Intervention: Physically castrated (PC) pigs
Number of subjects: 1408

Group type: EXPERIMENTAL
Intervention: RAC feeding
Number of subjects: 1408

Group type: COMPARATOR
Intervention: Control-fed pigs
Number of subjects: 1408

Group type: EXPERIMENTAL
Intervention: IC pigs
Number of subjects: 1408

Group type: COMPARATOR
Intervention: PC pigs
Number of subjects: 1408
Study: 22437659

Group type: EXPERIMENTAL
Intervention: Arthroscopic treatment followed by exercise therapy for 2 months
Number of subjects: 96

Group type: COMPARATOR
Intervention: Exercise therapy alone
Number of subjects: 96
Study: 20552353

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using Photofrin, HPD, ALA, or Foscan
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) for laryngeal cancers
Number of subjects: 518

Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT) compared to conventional therapies
Number of subjects: 518
Study: 18269366

Group type: EXPERIMENTAL
Intervention: Intensive Case Management (ICM)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 302
Study: 16325020

Group type: EXPERIMENTAL
Intervention: Continuous combined regimen: combined oestrogen/progestogen skin patches (releasing continuous 50 microg estradiol and 20 microg levonorgestrel/day)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Interrupted regimen: oestrogen-only patches (releasing 80 microg estradiol/day) for 4 days followed by combined oestrogen/progestogen patches (releasing continuous 50 microg estradiol and 20 microg levonorgestrel/day) for 3 days
Number of subjects: 59
Study: 14623524

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Letrozole and Anastrozole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breast-conserving surgery and radiotherapy
Number of subjects: 0
Study: 10824665

Group type: EXPERIMENTAL
Intervention: Exploratory factor analyses in group A
Number of subjects: 1472

Group type: EXPERIMENTAL
Intervention: Confirmatory factor analyses in group B
Number of subjects: 1472

Group type: EXPERIMENTAL
Intervention: Three-factor model with 12 items (W-BQ12)
Number of subjects: 1472
Study: 8787175

Group type: EXPERIMENTAL
Intervention: Relevant condition (counting stimuli)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Irrelevant condition (ignoring stimuli)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Short-RT subjects
Number of subjects: 2
Study: 2050424

Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg three times daily)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (960 mg three times daily)
Number of subjects: 128
Study: 6338840

Group type: EXPERIMENTAL
Intervention: Fasting for 7 days
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control regimen
Number of subjects: 13
Study: 30713016

Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin Glargine
Number of subjects: 0
Study: 27862066

Group type: EXPERIMENTAL
Intervention: AFXL treatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (untreated scars)
Number of subjects: 12
Study: 26399603

Group type: EXPERIMENTAL
Intervention: Early physical therapy for the first 4 weeks
Number of subjects: 220

Group type: COMPARATOR
Intervention: Usual care only for the first 4 weeks
Number of subjects: 220
Study: 22730470

Group type: EXPERIMENTAL
Intervention: Lesogaberan 60 mg twice daily
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Lesogaberan 120 mg twice daily
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Lesogaberan 180 mg twice daily
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Lesogaberan 240 mg twice daily
Number of subjects: 661

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 661
Study: 20942820

Group type: EXPERIMENTAL
Intervention: Person-centred approaches to nursing care practices (PCC)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Modifications to physical environment (PCE)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: PCC + PCE
Number of subjects: 605

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Usual Environment (UE)
Number of subjects: 605
Study: 19167011

Group type: EXPERIMENTAL
Intervention: New algorithm for predicting the culprit artery from ECG in inferior STEMI
Number of subjects: 187

Group type: COMPARATOR
Intervention: Previous algorithm for predicting the culprit artery from ECG in all-comers STEMI
Number of subjects: 187
Study: 16737869

Group type: EXPERIMENTAL
Intervention: Oral erythromycin (EM) 10 mg/kg every 6 hours for 2 days, followed by 4 mg/kg every 6 hours for another 5 days
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 15514409

Group type: EXPERIMENTAL
Intervention: ECT (suprathreshold right unilateral or bilateral ECT)
Number of subjects: 139
Study: 11444418

Group type: EXPERIMENTAL
Intervention: Enteric-coated garlic powder tablets with 9.6 mg allicin-releasing potential
Number of subjects: 46

Group type: COMPARATOR
Intervention: Matching placebo tablets
Number of subjects: 46
Study: 9272801

Group type: EXPERIMENTAL
Intervention: TMD group (Hi-SC TMD)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: TMD group (Lo-SC TMD)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study: 9120818

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil suspension without sodium lauryl sulfate (SLS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil suspension with sodium lauryl sulfate (SLS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cefuroxime axetil tablet formulation
Number of subjects: 24
Study: 2884853

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 297
Study: 31962179

Group type: EXPERIMENTAL
Intervention: Pre-ICU cold intravenous (i.v.) fluids
Number of subjects: 352

Group type: COMPARATOR
Intervention: No pre-ICU cold intravenous (i.v.) fluids
Number of subjects: 352
Study: 31690740

Group type: EXPERIMENTAL
Intervention: Early-evening bright light exposure (1200 lx, 4000 K) for 2.5 hours
Number of subjects: 12

Group type: COMPARATOR
Intervention: Late-evening light exposure (750 lx, 4000 K)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dim light
Number of subjects: 12
Study: 29208784

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) mouthwash
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neem mouthwash
Number of subjects: 60

Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 60
Study: 26163375

Group type: EXPERIMENTAL
Intervention: Self-controlled feedback (Self)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Yoked feedback (Yoked)
Number of subjects: 0
Study: 23343363

Group type: EXPERIMENTAL
Intervention: Client-centred occupational therapy (OT)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Usual care OT
Number of subjects: 269
Study: 21617527

Group type: EXPERIMENTAL
Intervention: L-theanine (400 mg/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18158312

Group type: EXPERIMENTAL
Intervention: Gelatin solution
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) (130/0.4)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Ringer's lactate solution
Number of subjects: 66
Study: 17347346

Group type: EXPERIMENTAL
Intervention: Composite measure of self-regulation (youth, parent, teacher report)
Number of subjects: 0
Study: 14521738

Group type: EXPERIMENTAL
Intervention: Diltiazem infusion (0.1 mg/kg/h)
Number of subjects: 40
Study: 10627344

Group type: EXPERIMENTAL
Intervention: Bioabsorbable polyglyconate screw (Endo‐Fix; Smith & Nephew, Andover, MA)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Metal screw
Number of subjects: 124
Study: 9407509

Group type: EXPERIMENTAL
Intervention: Low dose lisinopril (group 1)
Number of subjects: 25

Group type: COMPARATOR
Intervention: No ACE inhibitor therapy (group 2)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 25
Study: 1362778

Group type: EXPERIMENTAL
Intervention: Enteric coated sulfasalazine as Salazopyrin En‐tabs
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 2862808

Group type: EXPERIMENTAL
Intervention: Atracurium 2.5 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Atracurium 5 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fazadinium 3.75 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 100
Study: 30654658

Group type: EXPERIMENTAL
Intervention: Emotion-oriented coping style
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Psychological distress assessment using HADS
Number of subjects: 54
Study: 29321141

Group type: EXPERIMENTAL
Intervention: Multidisciplinary, aerobic, motor-cognitive and intensive rehabilitation treatment (MIRT) for 4 weeks
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group (no rehabilitation)
Number of subjects: 186
Study: 27497716

Group type: EXPERIMENTAL
Intervention: qPCR
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: NGS
Number of subjects: 4
Study: 25378424

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of autologous bone marrow mononuclear stem cells (BMSCs)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 120
Study: 22045413

Group type: EXPERIMENTAL
Intervention: Active recovery (cycling at 30% VO(2 max))
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: NMES (1 Hz/500 μs‐ON:OFF 2:6 s)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Passive recovery (seated)
Number of subjects: 13
Study: 19533583

Group type: EXPERIMENTAL
Intervention: Intervention group (11 homes)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (6 homes)
Number of subjects: 17
Study: 17651149

Group type: EXPERIMENTAL
Intervention: High-dose inhaled corticosteroids (ICS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Symptomatic steroid-free asthmatics
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-asthmatic controls
Number of subjects: 20
Study: 16092896

Group type: EXPERIMENTAL
Intervention: Experiential cognitive therapy (ExCT), 4 sessions
Number of subjects: 40

Group type: COMPARATOR
Intervention: Panic control program (PCP), 12 sessions
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Experiential cognitive therapy (ExCT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Panic control program (PCP)
Number of subjects: 40
Study: 12071157

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11359306

Group type: EXPERIMENTAL
Intervention: Astra Tech implants
Number of subjects: 66

Group type: COMPARATOR
Intervention: Brånemark System implants
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 66
Study: 7810934

Group type: EXPERIMENTAL
Intervention: Relatives of patients with sleep apnea-hypopnea syndrome
Number of subjects: 102
Study: 2194004

Group type: EXPERIMENTAL
Intervention: Iopanoic acid (1 gm daily for 21 days)
Number of subjects: 5
Study: 103852

Group type: EXPERIMENTAL
Intervention: Dental cones containing the antifibrinolytically active propylic ester of p‐hydroxybenzoic acid (PEPH)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Sulfanilamide and sulfathiazol
Number of subjects: 95
Study: 29943271

Group type: EXPERIMENTAL
Intervention: SLOWB (device-guided slow breathing)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No SLOWB (control group)
Number of subjects: 21
Study: 28740376

Group type: EXPERIMENTAL
Intervention: FP/FORM 500/20 µg
Number of subjects: 1765

Group type: EXPERIMENTAL
Intervention: FP/FORM 250/10 µg
Number of subjects: 1765

Group type: EXPERIMENTAL
Intervention: FP/FORM 500/20 µg and FP/FORM 250/10 µg
Number of subjects: 1765

Group type: COMPARATOR
Intervention: FP/FORM 500/20 µg, FP/FORM 250/10 µg, FORM
Number of subjects: 1765
Study: 24896141

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 19

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 19
Study: 23386653

Group type: EXPERIMENTAL
Intervention: Prednisolone (PRED) 7.5 mg once daily (n = 12)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Prednisolone (PRED) 30 mg once daily (n = 12)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 32
Study: 20955266

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg once daily
Number of subjects: 8000
Study: 19710500

Group type: EXPERIMENTAL
Intervention: laromustine and high-dose cytarabine (HDAC)
Number of subjects: 263

Group type: COMPARATOR
Intervention: high-dose cytarabine/placebo
Number of subjects: 263
Study: 17240287

Group type: EXPERIMENTAL
Intervention: 800 mcg daily oral folic acid
Number of subjects: 818

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 818
Study: 15566917

Group type: EXPERIMENTAL
Intervention: Fluid balance and volume administered on postoperative day 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Net fluid balance on postoperative day 2
Number of subjects: 0
Study: 12488264

Group type: EXPERIMENTAL
Intervention: Bimatoprost once daily
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Bimatoprost twice daily
Number of subjects: 602

Group type: COMPARATOR
Intervention: Timolol twice daily
Number of subjects: 602
Study: 10450256

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8651067

Group type: EXPERIMENTAL
Intervention: Onset of deafness before 18 months of age
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Younger children
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Self-esteem
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: External locus of control
Number of subjects: 42
Study: 2112634

Group type: EXPERIMENTAL
Intervention: Modular tube feeding recipe (MTF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Enteral regimens widely utilized in the nutritional support of burns
Number of subjects: 50
Study: 496555

Group type: EXPERIMENTAL
Intervention: Drug-free state serum calcium levels in patients with EPS
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Drug-free state serum magnesium levels in patients with EPS
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Neuroleptic dosage
Number of subjects: 22

Group type: COMPARATOR
Intervention: Serum calcium and magnesium levels during neuroleptic treatment
Number of subjects: 22
Study: 31931623

Group type: EXPERIMENTAL
Intervention: Threat agency
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Interdependent self‐construal
Number of subjects: 276

Group type: COMPARATOR
Intervention: Independent self‐construal
Number of subjects: 276
Study: 31897708

Group type: EXPERIMENTAL
Intervention: NAPP application into the pockets, adjunctive to NSPT
Number of subjects: 25

Group type: COMPARATOR
Intervention: NSPT alone (Control)
Number of subjects: 25
Study: 30458126

Group type: EXPERIMENTAL
Intervention: Ultra-pulse CO2 laser resurfacing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manual dermabrasion
Number of subjects: 20